• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".

作者信息

Suez Daniel, Stein Mark, Gupta Sudhir, Hussain Iftikhar, Melamed Isaac, Paris Kenneth, Darter Amy, Bourgeois Christelle, Fritsch Sandor, Leibl Heinz, McCoy Barbara, Gelmont David, Yel Leman

机构信息

Allergy, Asthma and Immunology Clinic PA, Irving, TX, USA.

Allergy Associates of the Palm Beaches, North Palm Beach, FL, USA.

出版信息

J Clin Immunol. 2017 Nov;37(8):739-740. doi: 10.1007/s10875-017-0438-y. Epub 2017 Sep 5.

DOI:10.1007/s10875-017-0438-y
PMID:28875256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5662656/
Abstract
摘要

相似文献

1
Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".对致编辑的信的回复，信的主题为“在临床试验中评估皮下注射免疫球蛋白（SCIG）的局部不良反应”
J Clin Immunol. 2017 Nov;37(8):739-740. doi: 10.1007/s10875-017-0438-y. Epub 2017 Sep 5.
2
Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.临床试验中皮下注射免疫球蛋白（SCIG）局部不良反应的评估。
J Clin Immunol. 2017 Aug;37(6):517-518. doi: 10.1007/s10875-017-0410-x. Epub 2017 Jul 10.
3
Skin Necrosis Following Subcutaneous Immunoglobulin (SCIg).皮下注射免疫球蛋白后的皮肤坏死
J Clin Immunol. 2017 Jan;37(1):27-28. doi: 10.1007/s10875-016-0346-6. Epub 2016 Oct 28.
4
Immunoglobulin Replacement Therapy for Primary Immunodeficiency.原发性免疫缺陷的免疫球蛋白替代疗法
Immunol Allergy Clin North Am. 2015 Nov;35(4):713-30. doi: 10.1016/j.iac.2015.07.006. Epub 2015 Sep 4.
5
Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.皮下注射免疫球蛋白IgPro20用于日本原发性免疫缺陷患者的成本最小化分析。
Clin Ther. 2014 Nov 1;36(11):1616-24. doi: 10.1016/j.clinthera.2014.08.007. Epub 2014 Sep 16.
6
Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.家庭皮下免疫球蛋白 G 治疗老年原发性免疫缺陷病患者的安全性和疗效。
Postgrad Med. 2011 Sep;123(5):186-93. doi: 10.3810/pgm.2011.09.2474.
7
Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.皮下免疫球蛋白治疗通过皮下快速推注与输注泵给药：回顾性分析。
Ann Allergy Asthma Immunol. 2013 Jul;111(1):51-5. doi: 10.1016/j.anai.2013.04.015. Epub 2013 May 22.
8
[Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].[皮下注射免疫球蛋白用于儿童原发性免疫缺陷的替代疗法]
Pol Merkur Lekarski. 2011 Jun;30(180):413-6.
9
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.对于原发性抗体缺陷患者，从静脉注射或16%皮下替代疗法转换为20%皮下免疫球蛋白疗法。
Int J Immunopathol Pharmacol. 2017 Mar;30(1):73-82. doi: 10.1177/0394632016681577. Epub 2016 Dec 7.
10
[Subcutaneous immunoglobulin substitution and therapy].[皮下免疫球蛋白替代与治疗]
Orv Hetil. 2011 Jan 9;152(2):64-7. doi: 10.1556/OH.2011.28940.

本文引用的文献

1
Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.临床试验中皮下注射免疫球蛋白（SCIG）局部不良反应的评估。
J Clin Immunol. 2017 Aug;37(6):517-518. doi: 10.1007/s10875-017-0410-x. Epub 2017 Jul 10.
2
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.新型20%皮下注射用人免疫球蛋白的疗效、安全性、耐受性及药代动力学：在欧洲针对原发性免疫缺陷患者开展的2/3期研究
Clin Exp Immunol. 2017 Jan;187(1):146-159. doi: 10.1111/cei.12866. Epub 2016 Oct 18.
3
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.北美原发性免疫缺陷病患者使用新型20%皮下注射用人免疫球蛋白的疗效、安全性及药代动力学
J Clin Immunol. 2016 Oct;36(7):700-12. doi: 10.1007/s10875-016-0327-9. Epub 2016 Aug 31.
4
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.新型 20%皮下免疫球蛋白制剂 IgPro20 治疗原发性免疫缺陷症患者的疗效和安全性。
J Clin Immunol. 2010 Sep;30(5):734-45. doi: 10.1007/s10875-010-9423-4. Epub 2010 May 8.
5
Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.新型10%静脉注射用液体免疫球蛋白制剂Privigen在原发性免疫缺陷患者中的安全性和有效性。
J Clin Immunol. 2009 Jan;29(1):137-44. doi: 10.1007/s10875-008-9231-2. Epub 2008 Sep 24.